Brevets

L’unité dépose régulièrement des brevets dans le cadre de la propriété intellectuelle avec le soutien des tutelles de l’UMR PIMIT, d’Inserm-Transfert et de CNRS Innovation.

2024

PCT/EP2025/053762. Disubstituted ferrocene compounds and their therapeutic use. EP24305250.3.

2023

PCT/EP23305746.2. New Ternatine-type cyclopeptides for use in therapy. CNRS: DI 16247-01

2021

PCT/EP2021/081631. Use of the last C-terminal residues M31/41 of ZIKV M ectodomain for triggering apoptotic cell death. Service valorisation Inserm-Transfert

EP21305818. Peptides derived from the spike protein of SARS-CoV-2 and uses thereof for diagnosis and vaccine purposes. Europeab Patent Office. Service valorisation Inserm-Transfert

EP20305021. Antigenic reactivity of a peptide mimicking the glycan loop of flaviviruses envelope protein. Service valorisation Inserm-Transfert

2020

EP 20305559.5. Fusion Proteins comprising the SARS-CoV-2 3 CLPRO catalytic domain and their uses for screening anti SARS-CoV-2 agents.

2019

WHO/2019/185579. Use of Quercetin-3-O-glucoside for the treatment of flavivirus infections.

crossmenuchevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram